MAIA Biotechnology, Inc. (MAIA)

NYSEAMERICAN: MAIA · Real-Time Price · USD
1.930
-0.080 (-3.98%)
Jul 10, 2025, 4:00 PM - Market closed
-3.98%
Market Cap 58.49M
Revenue (ttm) n/a
Net Income (ttm) -19.70M
Shares Out 30.31M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 424,583
Open 1.950
Previous Close 2.010
Day's Range 1.850 - 1.960
52-Week Range 1.400 - 4.240
Beta 0.05
Analysts n/a
Price Target n/a
Earnings Date Aug 8, 2025

About MAIA

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2022
Employees 13
Stock Exchange NYSEAMERICAN
Ticker Symbol MAIA
Full Company Profile

Financial Performance

Financial Statements

News

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer.

1 day ago - Business Wire

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress.

9 days ago - Business Wire

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board.

16 days ago - Business Wire

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies.

22 days ago - Business Wire

MAIA Biotechnology to Present at BIO International Convention 2025

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at BIO International Convention 2025.

4 weeks ago - Business Wire

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

MAIA Biotechnology, Inc. MAIA on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.

5 weeks ago - Benzinga

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial.

5 weeks ago - Business Wire

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer.

5 weeks ago - Business Wire

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $695,000.

6 weeks ago - Business Wire

MAIA Biotechnology Announces Private Placement of Approximately $669,500

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $669,500.

6 weeks ago - Business Wire

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

2 months ago - Business Wire

MAIA Biotechnology Announces Director Participation in Recent Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Director Participation in Recent Private Placement.

2 months ago - Business Wire

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

CHICAGO--(BUSINESS WIRE)--CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement.

2 months ago - Business Wire

MAIA Biotechnology Announces $1.08 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.08 Million Private Placement.

2 months ago - Business Wire

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders.

3 months ago - Business Wire

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.

3 months ago - Business Wire

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug.

4 months ago - Business Wire

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO.

4 months ago - Business Wire

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients.

4 months ago - Business Wire

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...

4 months ago - Business Wire

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million.

4 months ago - Business Wire

MAIA Biotechnology Announces Private Placement of $2,715,000

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of $2,715,000.

5 months ago - Business Wire

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer.

5 months ago - Business Wire

MAIA Biotechnology to Present at Biotech Showcase 2025

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2025.

6 months ago - Business Wire

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings.

7 months ago - Business Wire